Document is current
Any future updates will be listed below
-
Authors
Wang, Rutao
Takahashi, Kuniaki
Garg, Scot
Thuijs, Daniel J. F. M.
Kappetein, Arie Pieter
Mack, Michael J.
Morice, Marie-Claude
Mohr, Friedrich-Wilhelm
Curzen, Nick
Davierwala, Piroze
Milojevic, Milan
van Geuns, Robert Jan
Head, Stuart J.
Onuma, Yoshinobu
Holmes, David R. Jr
Serruys, Patrick W. https://orcid.org/0000-0002-9636-1104
-
Funding
Funding for this research was provided by:
German Foundation of Heart Research
- License Information
-
More Information
Article History
Received: 23 October 2020
Accepted: 29 December 2020
First Online: 30 January 2021
Compliance with ethical standards
:
: Dr. Serruys reports personal fees from Biosensors, Micel Technologies, Sinomedical Sciences Technology, Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. Dr. Kappetein reports to work as an employee of Medtronic, outside the submitted work. Dr. Head reports to work as a full-time employee of Medtronic outside the scope of this work. Dr. Morice reports to work as the CEO of CERC, a CRO which was never involved in the SYNTAX trial at any level, except that submitted the 10 years additional follow-up (for free) to French authorities to get approval. Dr. van Geuns reports personal fees from Abbott vascular, grants and personal fees from AstraZeneca, grants and personal fees from Amgen, grants and personal fees from Boston Scientific, personal fees from Sanofi, outside the submitted work. All other authors have no disclosures.
